



Adaptive Biotechnologies Appoints Francis Lo as Chief People Officer

May 3, 2019

SEATTLE, WA, May 3, 2019 — Adaptive Biotechnologies today announced the appointment of Francis Lo as Chief People Officer, overseeing development and execution of the company's Human Capital strategy. Mr. Lo comes to Adaptive from Whole Foods Market: An Amazon Company, where he was Vice President of Human Resources.

"We are deeply committed to providing our employees with a thriving work environment that inspires creativity, innovation and growth," said Chad Robins, CEO and co-founder of Adaptive Biotechnologies. "Francis' experience in designing and leading People practices and strategies for large scale, global companies makes him well matched for the role of Chief People Officer at Adaptive as we continue to scale our business at a rapid pace."

While at Whole Foods Market, Mr. Lo led the development and implementation of transformative HR strategies for all Corporate Functions, oversaw enterprise Learning & Development, and launched essential Talent Management practices. After Amazon's acquisition of Whole Foods Market, he also guided the company through key post- integration initiatives, including internal reorganizations and talent transfers, compensation and job leveling, policy and compliance alignment, leadership development, and training.

Previously, Francis held leadership roles in Sales, Operations, Corporate Strategy, Consumer Insights, and Human Resources across domestic and international markets at Frito Lay, PepsiCo, and Starbucks.

"I am excited to join Adaptive to work with this team of passionate, mission-oriented people," said Mr. Lo. "This is an incredible opportunity to be part of a company that is poised to write a new chapter in precision health and positively impact human health and happiness."

About Adaptive Biotechnologies

Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people's lives by learning from the wisdom of their adaptive immune systems. Adaptive's proprietary immune medicine platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products that will transform the way diseases such as cancer, autoimmune conditions, and infectious diseases are diagnosed and treated. For more information, please visit adaptivebiotech.com.

CONTACT:

Adaptive Biotechnologies

Beth Keshishian

917-912-7195

media@adaptivebiotech.com